← Science Nature Medicine · Nov 4, 2026

Perioperative ivonescimab in resectable NSCLC: combination MPR 70.1% (operated) / 59.5% (FAS)

Neoadjuvant ivonescimab alone or with chemotherapy was followed by surgery and adjuvant ivonescimab in patients with resectable NSCLC. Among operated patients, major pathological response (MPR) was observed in 6/10 receiving monotherapy (60.0%) and 47/67 receiving combination treatment (70.1%); by full analysis set (FAS, all enrolled), combination MPR was 59.5%. The combination cohort met its prespecified historical-control-based primary endpoint (80% CI lower bound exceeded 41% historical control).

Mechanism figure
Perioperative ivonescimab regimen in resectable NSCLC. Illustration generated with AI; not a figure from the original paper.

Background and open questions

Perioperative immunotherapy has improved outcomes in resectable non-small cell lung cancer (NSCLC), but the optimal regimen is still evolving. Ivonescimab is a bispecific antibody targeting both PD-1 and VEGF, combining checkpoint inhibition with anti-angiogenic activity in a single molecule. Whether this dual mechanism could improve pathological responses in the neoadjuvant setting remained untested.

Study design

This nonrandomized, noncomparative phase 2 trial enrolled 90 patients with resectable NSCLC. Patients received neoadjuvant ivonescimab alone (11 patients) or with platinum-based chemotherapy (79 patients), followed by surgery and adjuvant ivonescimab. The primary endpoint was major pathological response (MPR), with the combination cohort designed to test against a historical control.

Key results

  • In the monotherapy cohort, 6 of 10 operated patients achieved MPR (60.0%).
  • In the combination cohort, 47 of 67 operated patients achieved MPR (70.1%), meeting the prespecified primary endpoint.
  • Grade ≥3 treatment-related adverse events occurred in 4 of 11 monotherapy patients and 24 of 79 combination patients.
  • No grade ≥3 hemorrhage or treatment-related deaths occurred.

Mechanistic interpretation

The dual PD-1 and VEGF blockade may enhance antitumor immunity by both relieving T-cell suppression and normalizing the tumor vasculature, potentially improving immune cell infiltration. The pathological response rates suggest this approach warrants further investigation in randomized trials.

Limitations

  • The study design is nonrandomized and noncomparative; it does not demonstrate superiority over current perioperative standards.
  • Sample sizes are small, particularly in the monotherapy cohort (10 evaluable for surgical response).
  • Long-term survival outcomes are not yet available.

Authors and source

Nature Medicine (2026). Published online 4 November 2026. https://doi.org/10.1038/s41591-026-04745-4.

Numbers are as reported by the authors. Corrections: contact@inlightbio.com.

Related science

Get new science briefs every week

One email, with links to every paper. Reports and custom landscapes: contact@inlightbio.com.

Opens your email app with a pre-filled request; we add you by hand. Free, unsubscribe any time.